Storia in 2 fonti

Ozempic, Wegovy may lower fracture risk in diabetes patients

A recent study reveals that semaglutide, the active ingredient in Ozempic and Wegovy, may enhance bone strength in Type 2 diabetes patients while aiding weight loss.

Raccontata da

newsbytesapp.com

healio.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

newsbytesapp.comStai leggendo1 mese fa

Ozempic, Wegovy may lower fracture risk in diabetes patients

Noto che questo articolo riguarda medicina/sanità, non tech, AI, business o alcun argomento di Warptech. Non è rilevante per il target (manager IT, CTO, responsabili AI italiani). Se comunque vuoi il riassunto come esercizio: --- Semaglutide users had 15% fewer bone fractures than other weight loss drugs in a 59,000-patient study (ENDO 2026). Bone health monitoring gains clinical importance in weight loss programs, expanding focus on long-term medication safety outcomes.

originale

healio.com1 mese fa

Semaglutide linked to lower fracture risk than other drugs in type 2 diabetes

CHICAGO — Adults with type 2 diabetes may have lower risk for fractures if they use semaglutide compared with other medications, according to data presented at ENDO 2026. As Healio previously reported, a retrospective…

Ozempic, Wegovy may lower fracture risk in diabetes patients

Semaglutide linked to lower fracture risk than other drugs in type 2 diabetes

Timeline cronologica

Ozempic, Wegovy may lower fracture risk in diabetes patients

Semaglutide linked to lower fracture risk than other drugs in type 2 diabetes